616 related articles for article (PubMed ID: 27028851)
1. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
2. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
3. Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients.
Ronowicz A; Janaszak-Jasiecka A; Skokowski J; Madanecki P; Bartoszewski R; Bałut M; Seroczyńska B; Kochan K; Bogdan A; Butkus M; Pęksa R; Ratajska M; Kuźniacka A; Wasąg B; Gucwa M; Krzyżanowski M; Jaśkiewicz J; Jankowski Z; Forsberg L; Ochocka JR; Limon J; Crowley MR; Buckley PG; Messiaen L; Dumanski JP; Piotrowski A
Hum Mutat; 2015 Nov; 36(11):1088-99. PubMed ID: 26219265
[TBL] [Abstract][Full Text] [Related]
4. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
5. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
6. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
7. Concordance of genomic alterations between primary and recurrent breast cancer.
Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
[TBL] [Abstract][Full Text] [Related]
8. Comparative genomic analysis reveals bilateral breast cancers are genetically independent.
Song F; Li X; Song F; Zhao Y; Li H; Zheng H; Gao Z; Wang J; Zhang W; Chen K
Oncotarget; 2015 Oct; 6(31):31820-9. PubMed ID: 26378809
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
11. Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization.
Sawada T; Yamamoto E; Suzuki H; Nojima M; Maruyama R; Shioi Y; Akasaka R; Kamimae S; Harada T; Ashida M; Kai M; Adachi Y; Yamamoto H; Imai K; Toyota M; Itoh F; Sugai T
Genes Chromosomes Cancer; 2013 Feb; 52(2):140-9. PubMed ID: 23073979
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
13. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
14. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.
Bambury RM; Bhatt AS; Riester M; Pedamallu CS; Duke F; Bellmunt J; Stack EC; Werner L; Park R; Iyer G; Loda M; Kantoff PW; Michor F; Meyerson M; Rosenberg JE
BMC Cancer; 2015 Apr; 15():242. PubMed ID: 25886454
[TBL] [Abstract][Full Text] [Related]
15. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH
Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515
[TBL] [Abstract][Full Text] [Related]
16. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
17. What to expect from high throughput genomics in metastatic breast cancers?
Onesti CE; Vicier C; André F
Breast; 2015 Nov; 24 Suppl 2():S19-22. PubMed ID: 26238439
[TBL] [Abstract][Full Text] [Related]
18. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
[TBL] [Abstract][Full Text] [Related]
19. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
Arnedos M; Scott V; Job B; De La Cruz J; Commo F; Mathieu MC; Wolp-Diniz R; Richon C; Campone M; Bachelot T; Dalenc F; Dessen P; Lacroix L; Lazar V; Soria JC; Delaloge S; Andre F
Eur J Cancer; 2012 Oct; 48(15):2293-9. PubMed ID: 22840369
[TBL] [Abstract][Full Text] [Related]
20. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
André F; Bachelot T; Commo F; Campone M; Arnedos M; Dieras V; Lacroix-Triki M; Lacroix L; Cohen P; Gentien D; Adélaide J; Dalenc F; Goncalves A; Levy C; Ferrero JM; Bonneterre J; Lefeuvre C; Jimenez M; Filleron T; Bonnefoi H
Lancet Oncol; 2014 Mar; 15(3):267-74. PubMed ID: 24508104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
